Weekly Investment Analysts’ Ratings Updates for Adamis Pharmaceuticals (ADMP)
Several brokerages have updated their recommendations and price targets on shares of Adamis Pharmaceuticals (NASDAQ: ADMP) in the last few weeks:
- 11/30/2017 – Adamis Pharmaceuticals was given a new $10.00 price target on by analysts at B. Riley. They now have a “buy” rating on the stock.
- 11/30/2017 – Adamis Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
- 11/20/2017 – Adamis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. “
- 11/15/2017 – Adamis Pharmaceuticals was given a new $10.00 price target on by analysts at B. Riley. They now have a “buy” rating on the stock.
Adamis Pharmaceuticals Corp (NASDAQ ADMP) traded down $0.05 during mid-day trading on Tuesday, reaching $4.00. 689,000 shares of the company traded hands, compared to its average volume of 730,169. Adamis Pharmaceuticals Corp has a 52 week low of $2.55 and a 52 week high of $6.45. The company has a current ratio of 3.93, a quick ratio of 3.79 and a debt-to-equity ratio of 0.06.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.